PLGA from PolySciTech used in development of anti-MRSA nanoparticles

 

Bacterial infections in bone tissue are extremely difficult to treat even with extensive antibiotic therapy as drug transport into these hard to reach areas is minimal. Recently, researchers at Temple University (Philadelphia, PA) used PLGA (AP063) to create rifampicin loaded nanoparticles to treat MRSA bone infections. This research holds promise to reduce morbidity associated with these conditions. Read More: Guo, Pengbo, Hui Yi Xue, Bettina A. Buttaro, Ngoc T. Tran, and Ho Lun Wong. "Enhanced eradication of intracellular and biofilm-residing methicillin-resistant Staphylococcus aureus (MRSA) reservoirs with hybrid nanoparticles delivering rifampicin." International Journal of Pharmaceutics (2020): 119784. https://www.sciencedirect.com/science/article/pii/S0378517320307699

“Abstract: Osteomyelitis carries a high risk of recurrence even after extended, aggressive antibiotic therapy. One of the key challenges is to eradicate the reservoirs of methicillin-resistant Staphylococcus aureus (MRSA) inside the host bone cells and their biofilms. Our goal is to develop rifampicin loaded lipid-polymer hybrid nanocarriers (Rf-LPN) and evaluate if they can achieve enhanced rifampicin delivery to eradicate these intracellular and biofilm-residing MRSA. After optimization of the composition, Rf-LPN demonstrated size around 110 nm in diameter that remained stable in serum-supplemented medium, drug payload up to 11.7% and sustained rifampicin release for 2 weeks. When comparing Rf-LPN with free rifampicin, moderate but significant (p < 0.05) improvement of the activities against three osteomyelitis-causing bacteria (USA300-0114, CDC-587, RP-62A) in planktonic form were observed. In comparison, the enhancements in the activities against the biofilms and intracellular MRSA by Rf-LPN were even more substantial. The MBEC50 values against USA300-0114, CDC-587, and RP-62A were 42 vs 155, 70 vs 388, and 265 ng/ml vs over 400 ng/ml, respectively, and up to 18.5-fold reduction in the intracellular MRSA counts in osteoblasts was obtained. Confocal microscope images confirmed extensive accumulation of Rf-LPN inside the biofilm matrix and MRSA-infected osteoblasts. Overall, in this proof-of-concept study we have developed and validated the strategy to exploit the nanoparticle-cell and nanoparticle-biofilm interactions with a new rifampicin nanoformulation for prevention of osteomyelitis recurrence and chronicity caused by the elusive MRSA. Keywords: Nanoparticles Antibiotic Rifampicin MRSA Osteomyelitis.”